Anika Therapeutics Inc. (NASDAQ:ANIK) has earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Analysts have set a 12-month consensus price objective of $57.00 for the company and are predicting that the company will post $0.54 EPS for the current quarter, according to Zacks. Zacks has also assigned Anika Therapeutics an industry rank of 98 out of 265 based on the ratings given to its competitors.

Separately, Barrington Research increased their price target on shares of Anika Therapeutics from $53.00 to $57.00 and gave the stock an “outperform” rating in a report on Friday, October 27th.

In other news, insider Richard Hague sold 5,250 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $54.48, for a total value of $286,020.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Charles H. Sherwood sold 3,293 shares of the firm’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $60.04, for a total transaction of $197,711.72. The disclosure for this sale can be found here. Insiders have sold 43,886 shares of company stock worth $2,606,455 over the last three months. 6.57% of the stock is currently owned by insiders.

Several large investors have recently bought and sold shares of ANIK. Kayne Anderson Rudnick Investment Management LLC increased its position in Anika Therapeutics by 16.4% during the third quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,656,918 shares of the biotechnology company’s stock worth $96,101,000 after purchasing an additional 233,325 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Anika Therapeutics by 76.8% during the second quarter. Bank of New York Mellon Corp now owns 490,433 shares of the biotechnology company’s stock valued at $24,199,000 after acquiring an additional 213,055 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Anika Therapeutics by 13.8% during the second quarter. Dimensional Fund Advisors LP now owns 878,006 shares of the biotechnology company’s stock valued at $43,321,000 after acquiring an additional 106,307 shares during the last quarter. Sei Investments Co. acquired a new stake in shares of Anika Therapeutics during the third quarter valued at about $6,161,000. Finally, Wells Fargo & Company MN increased its position in shares of Anika Therapeutics by 25.0% during the third quarter. Wells Fargo & Company MN now owns 209,928 shares of the biotechnology company’s stock valued at $12,176,000 after acquiring an additional 42,015 shares during the last quarter. 84.87% of the stock is currently owned by hedge funds and other institutional investors.

Anika Therapeutics (NASDAQ ANIK) opened at $53.65 on Thursday. The stock has a market cap of $783.53, a P/E ratio of 25.09, a price-to-earnings-growth ratio of 2.81 and a beta of 1.46. Anika Therapeutics has a 52 week low of $41.64 and a 52 week high of $60.29.

Anika Therapeutics (NASDAQ:ANIK) last released its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $0.46 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.05. The firm had revenue of $27.18 million for the quarter, compared to analyst estimates of $27.44 million. Anika Therapeutics had a net margin of 28.23% and a return on equity of 13.40%. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.59 earnings per share. research analysts forecast that Anika Therapeutics will post 1.9 earnings per share for the current year.

WARNING: “Brokerages Anticipate Anika Therapeutics Inc. (ANIK) to Post $0.54 EPS” was published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/12/07/brokerages-anticipate-anika-therapeutics-inc-anik-to-post-0-54-eps.html.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Get a free copy of the Zacks research report on Anika Therapeutics (ANIK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.